Oct 30, 2015 - patients were treated with 150mg or 110mg dabigatran twice-daily ... In the warfarin group we observed 9 (6%) pocket hematomas as.
490
Optimising cardiac pacing / Can we improve assessment of cardiovascular disease risk?
erative bleeding complications and thromboembolic events were compared. The patients were treated with 150mg or 110mg dabigatran twice-daily according to creatinine clearance or with warfarin with target INR>2. In all cases the anticoagulation was discontinued 12h before the procedure and initialised within 48h after the procedure without bridging. All bleeding and thromboembolic complications occurring within 30 days were reported. Results: Patients in both groups were of similar age (72±11 vs 74±9years, p=n.s.) and were mainly male (64% vs 66%, p=n.s.). The mean procedural time was similar in both groups (60±30 vs 58±39min, p=n.s.). In 2 patients with dabigatran and in 3 patients with warfarin a submusculer implantation was performed (p=n.s.) Most of the patients in both groups received dual chamber or cardiac resynchronization devices (71% vs 72%) as opposed to single chamber systems (29% vs 28%). In the warfarin group we observed 9 (6%) pocket hematomas as compared with 3 (3%) in the dabigatran group (p=n.s.). Two complications in the warfarin group needed a surgical intervention as opposed to non in the dabigatran group (p
